Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial

Journal of Hypertension

Volumn 27, Issue 8, 2009, Pages 1705-1712

  Yasuno, Shinji ^a   Ueshima, Kenji ^a   Oba, Koji ^a   Fujimoto, Akira ^a   Ogihara, Toshio ^b   Saruta, Takao ^c   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular events; Echocardiography; Hypertension; Left ventricular hypertrophy; Serum creatinine; Target organ damage

Indexed keywords

AMLODIPINE; CANDESARTAN; CREATININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; JAPAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVAL;

EID: 68449094440     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832c6968     Document Type: Article

References (30)

1. Cohuet G, Struijker-Boudier H. Mechanism of target organ damage caused by hypertension: therapeutic potential. Phamacol Ther 2006; 111:81-89.
2. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trial. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
3. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45:813-827.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
5. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29 Suppl:S1-S105.
6. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
7. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
8. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
9. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al., and the MAVI Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829-1835.
10. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
11. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
12. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
13. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15:1021-1028.
14. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
15. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al., for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008; 51:393-398.
16. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, et al., CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26:979-990.
17. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24:613-634.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
19. Ghali WA, Quan H, Brant R, van Meile G, Norris CM, Faris PD, et al., APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) Investigators. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001; 286:1494-1497.
20. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 2006; 48:2285-2292.
21. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 2006; 31:305-316.
22. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens 2005; 23 (suppl 1):S27-S33.
23. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
24. Death and DALY estimates for 2002 by cause for WHO Member States: Burden of Disease statistics. World Health Organization, http://www.who.int/entity/ healthinfo/statistics/bodgbddeathdalyestimates.xls. [Accessed 30 April 2008]
25. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347-354.
26. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14:881-887.
27. Kramer H, Jacobs DR Jr, Bild D, Post W, Saad MF, Detrano R, et al. Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46:38-43.
28. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
29. Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006; 21:2780-2787.
30. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007; 50:723-728.